{"entity":{"id":"nct06745908","kind":"trial","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","aka":[],"tldr":"A phase 3 trial of Nogapendekin alfa inbakicept, Tislelizumab and Docetaxel in non-small-cell lung cancer, run by ImmunityBio, Inc., now recruiting.","summary":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In is a phase 3 interventional study registered as NCT06745908 by ImmunityBio, Inc., with 507 participants planned, started 2025-10-01 and due to reach its primary completion in 2028-09. Interventions recorded: N-803, Tislelizumab, Docetaxel and Prior failed checkpoint inhibitor.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06745908","url":"https://clinicaltrials.gov/study/NCT06745908"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytokine-therapy","cytotoxic-chemotherapy"],"targets":[],"drugs":["nogapendekin-alfa","tislelizumab","docetaxel"],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06745908","phase":"3","setting":"Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy","sponsor":"ImmunityBio, Inc.","participation":[{"nct":"NCT06745908","source":"https://clinicaltrials.gov/study/NCT06745908","fetchedAt":"2026-10-07T16:54:58.037Z","studySha256":"b99feaa0edc6049537ed2603578dba623a6f40ab83f4b0d09527a645ecac9b42","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-27","leadSponsor":"ImmunityBio, Inc.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"90 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":507,"enrolmentType":"ESTIMATED","siteCount":36,"recruitingSiteCount":34,"countries":["Canada","United Kingdom","United States"]}],"started":"2025-10-01","startedType":"actual","enrolled":507,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06745908/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}]}}